Global Stem Cells Group (GSCG) and Dr. Yanti Aesthetic Clinic Elevate Regenerative Medicine Landscape with New Stem Cell Center in Jakarta
Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide.
In a groundbreaking partnership with the esteemed Dr. Yanti Aesthetic Clinic, GSCG introduces its third Stem Cell Center in Indonesia, complementing existing facilities in Surabaya and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fourth location in Bali in the near future.
The launch of the Stem Cell Center in Jakarta serves as a beacon of innovation, the International Society for Stem Cell Application (ISSCA), GSCG’s educational division, conducted a groundbreaking training session alongside Dr. Alan Gaveck. This session spotlighted the transformational potential of NK cell therapies in treating Cancer and Anti-aging concerns, further cementing GSCG’s pioneering influence.
A distinctive feature of this collaboration is the authorization granted to Dr. Yanti Aesthetic Clinic to leverage GSCG’s brand, technologies, products, and treatment protocols. Operating as a franchise, the center proudly carries the brand, adhering to meticulous organizational guidelines, while being owned and operated by Dr. Yanti Aesthetic Clinic. This symbiotic arrangement seamlessly merges shared expertise with individual ownership, fostering a harmonious blend of vision and innovation.
Beyond its role as a clinical hub, the newly inaugurated Stem Cell Center will also serve as a focal point for ISSCA’s training initiatives in Asia. In addition to the pioneering NK cell therapy training conducted at the clinic, the center will facilitate educational programs to empower medical professionals across the continent with cutting-edge insights and advancements in regenerative medicine.
Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, shared his insights during the inaugural event, stating, “Global Stem Cells Group is dedicated to democratizing regenerative medicine access on a global scale. We encourage physicians to embrace the clinical and aesthetic applications of stem cell therapy, enabling patients around the world to experience the transformative benefits of regenerative treatments.”
Reflecting on the journey that led to this momentous occasion, Novas continued, “Dr. Yanti and I met in Brussels back in 2018, when this ambitious endeavor was but a vision. Today, as we witness the fruition of that vision, I express my profound gratitude for the privilege of collaborating with Dr. Yanti Aesthetic Clinic in ushering in the future of regenerative medicine.”
Dr. Yanti Kushmiran, Director of the DR. Yanti Aesthetic Clinic, echoed these sentiments, stating, “Our partnership with GSCG, a trailblazer with over a decade of pioneering work, resonates deeply with our commitment to excellence. The establishment of our third Stem Cell Center in Indonesia under the esteemed Global Stem Cells Group brand strengthens our ability to provide enhanced services to our patients, ushering in a new era of regenerative healthcare.”
With the inauguration of the Stem Cell Center in Jakarta, GSCG and Dr. Yanti Aesthetic Clinic take a significant stride towards advancing regenerative medicine’s frontiers. This landmark collaboration is poised to shape the future of medical care, leveraging cutting-edge technologies and expertise to benefit patients across the Asian continent and beyond.
About Dr. Yanti Aesthetic Clinic:
Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.
About the International Society for Stem Cell Application (ISSCA):
The International Society for Stem Cell Application (ISSCA) serves as the educational arm of Global Stem Cells Group (GSCG), dedicated to promoting knowledge and expertise in stem cell therapy and regenerative medicine. ISSCA empowers medical professionals across the globe with essential insights and advancements in the field.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group Announces New President of the International Society for Stem Cell Application (ISSCA)
Miami, Florida – Global Stem Cells Group, a leading organization in the field of regenerative medicine, is pleased to announce the appointment of Dr. Salih Yildirim as the new President of the International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group. Dr. Yildirim previously held the position of Director of Overseas Operations at ISSCA.
Dr. Salih Yildirim brings a wealth of experience and expertise to his new role as President of ISSCA. Having previously served as the Director of Overseas Operations, Dr. Yildirim has demonstrated his exceptional leadership skills and strategic vision throughout his career. He has played a vital role in expanding ISSCA’s international presence and fostering collaborations with stakeholders worldwide.
In a statement regarding the appointment, Dr. Daeyong Kim, the former President of ISSCA, expressed his confidence in Dr. Yildirim’s ability to lead the organization. Dr. Kim stated, “I think you are the best leader and the most prepared to be the President of ISSCA. Therefore, I think you should be the head of ISSCA.” Dr. Kim will now transition to other support functions within ISSCA.
Benito Novas, head of Public Relations for ISSCA, expressed his admiration for Dr. Salih Yildirim’s professional qualities. Novas said, “I have known and worked with Dr. Salih for more than 10 years, and I am honored to have him as President within the company. During these years, he has proven to be an exceptional leader with a great vision for ISSCA.”
ISSCA’s objectives under the leadership of Dr. Salih Yildirim will include advancing the understanding and application of stem cell therapies, promoting scientific research and collaboration among professionals in the field, and advocating for the ethical and responsible use of regenerative medicine worldwide. Dr. Yildirim’s extensive experience in business development, international relations, and regenerative medicine will undoubtedly contribute to the achievement of these objectives.
About Dr. Salih Yildirim:
Dr. Salih Yildirim holds a bachelor’s and master’s degrees in business administration from Cleveland State University (United States) and a Ph.D. in health management from the University of Health Sciences. He has held various key positions throughout his career, including Director of Overseas Operations at ISSCA. Dr. Yildirim is currently the General Manager of BioTrend Medical International, a biotechnology firm specializing in genetics, molecular biology, and stem cell technologies. He also serves as the chief executive officer of ReGen.IC Clinic, specializing in regenerative medicine and stem cell applications. Additionally, he is a member of the International Society for Stem Cell Application’s Board of Directors and the Global Stem Cell Group’s Board of Directors and International Operations Manager. Dr. Yildirim is also a member of Istanbul Atlas University’s Board of Directors. He is married and a proud father.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
International Society for Stem Cell Applications Launches Advanced Turkish Hair Transplant Certification Program in Cancun
Miami, Florida – The International Society for Stem Cell Applications (ISSCA) is thrilled to announce the launch of its newest program, the Advanced Turkish Hair Transplant Certification. This pioneering training and certification initiative will take place from December 8th to 10th at the prestigious Cellular Hope Institute Facility in Cancun, Mexico. Physicians are encouraged to register promptly as the program is expected to fill up quickly.
Turkey has earned a global reputation for providing the finest hair transplants worldwide. Some of the hair transplant experts from Turkey who have developed and perfected this procedure are now willing to share their secrets with any physician who seeks to excel in hair restoration procedures in their home country. The demand for hair regrowth, hair restoration, and hair transplant procedures is growing by the day as men and women realize they do not have to suffer from the embarrassment of thinning hair and bare scalps anymore.
The Advanced Turkish Hair Transplant Certification program offers a comprehensive curriculum encompassing cutting-edge hair transplant procedures. Participants will engage in both theoretical and practical training sessions, helping to assist their mastery of this rapidly expanding field. They will have the extraordinary opportunity to practice hair transplant surgeries under the supervision and guidance of world-renowned experts in the field, including Veysel Cabalar, Asli Uslu, and Emere Tuncinar, who bring their wealth of experience and knowledge to the program.
In addition to hair transplant surgery, the program’s curriculum will cover workshops on advanced hair restoration techniques such as exomes, stem cells, and platelet-rich plasma treatments. Participants will learn how to select suitable patients for these different hair restoration methods and gain hands-on experience in preparing, storing, and administering exosomes, stem cells, and platelet-rich plasma to promote hair regrowth. Armed with this expertise, we believe participants will return to their own clinics with confidence, ready to deliver these transformative procedures for the benefit of their patients.
Dr. Salih Yildirim, ISSCA President, expressed his delight in fulfilling the organization’s mission of expanding the reach of new regenerative medicine technologies to doctors and patients worldwide: “The Advanced Turkish Hair Transplant Certification program exemplifies our commitment to advancing the field of regenerative medicine. We are proud to provide doctors with the tools and knowledge to bring the latest hair restoration techniques to their patients.”
Benito Novas, ISSCA Vicepresident , added, “We are excited to bring this groundbreaking Turkish training to Cancun, offering local doctors and physicians across Latin America the opportunity to learn from the best. Our collaboration with the Cellular Hope Institute Facility underscores our dedication to providing exceptional educational experiences that benefit medical professionals and patients alike.”
The program will include theoretical sessions on scalp and hair follicle anatomy, patient evaluation, and surgical preparation for hair transplant procedures. Detailed workshops on graft extraction and implantation techniques will also be conducted, enabling participants to refine their skills and achieve realistic, outstanding results. From patient evaluations to postoperative care protocols, the hands-on surgical sessions will encompass every aspect of the hair transplant process.
The Advanced Turkish Hair Transplant Certification program by ISSCA offers an invaluable opportunity for doctors seeking to excel in the field of hair transplantation. Participants will gain comprehensive knowledge, refine their surgical techniques, and stay abreast of the latest advancements in hair regrowth, hair restoration, and hair transplants.
To learn more about the Advanced Turkish Hair Transplant Certification program and register for this transformative educational experience, please visit the official ISSCA website at www.issca.com.
About ISSCA
The International Society for Stem Cell Applications (ISSCA) is a multidisciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through advances in regenerative medicine. By bringing together worldwide researchers and healthcare practitioners, ISSCA aims to bridge the gap between cutting-edge scientific research and compassionate, effective patient care.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
International Society for Stem Cell Application (ISSCA) and Marmara University Launch Stem Cell and Regenerative Medicine Fellowship Program in Turkey
Participants in the program will have access to over 200 hours of valuable online content and hands-on laboratory practice in the state-of-the-art facilities at Marmara University and StemBio. Generally, the program will cover a series of topics related to the general principles of regenerative medicine, including:
- Stem cell biology;
- Evidence-based treatments; and
- Tissue engineering.
Hear from Certified and Established Industry Leaders
The Stem Cell and Regenerative Medicine Fellowship Program aims to provide attendees with the chance to meet, interact, and learn from ISSCA-certified doctors, scientists, experts, and Marmara University professors with in-depth expertise in the field. There will be seven days of in-person training and a comprehensive digital course offering practical experience in stem cell classifications and laboratory applications, with a high emphasis on Good Manufacturing Practice (GMP) guidelines.
Learn About the Best Stem-Cell Application Practices and Procedures in Clinical and Manufacturing Operations
By attending the program, participants should be able to gain valuable answers to the “how to” questions related to the practical applications of stem cell biology and regenerative medicine in research laboratories and manufacturing facilities. Attendees can expect to learn the following:
- How to culture stem cells;
- How to meet quality control standards;
- How to comply with cGMP functions;
- How to operate within the recommended clinical procedures;
- How to apply and implement the regulations for stem cell processing in a certified manufacturing facility; and
- How to apply clinical guidelines and regulatory policies when developing a GMP facility
Besides, the seven-day fellowship program will also offer participants resources to bolster their stem cell operations, including copies of presentations, procedural guidelines, and all forms and documentation related to a GMP facility.
Moreover, the Stem Cell and Regenerative Medicine Fellowship Program will cover a range of clinical procedures, including:
- Tissue processing;
- Isolation of mesenchymal stem cells;
- Culture, Expansion and cryopreservation; and
- Clinical Application of stem cells for wide-ranging indications: participants will get case books and complete protocols for about 30 indications.
Why Attend the Stem Cell and Regenerative Medicine Fellowship Program?
The program provides a learning experience for medical professionals and scientists who’d love to further their knowledge and skills in stem cells and regenerative medicine. Attendees will get the opportunity to learn from the top professionals in the field and gain practical hands-on experience in world-class laboratory facilities.
Here’s what Global Stem Cells Global’s CEO, Benito Novas, had to say: “We are delighted to hold the Stem Cells and Regenerative Medicine Fellowship Program, which is designed to provide participants with the opportunity to gain and further their knowledge in stem cell biology and tissue engineering. In addition, ISSCA’s partnership with Marmara University will ensure attendees have access to professors with deep knowledge in the field and practical training in stem cell and regenerative medicine.”
For more information on the Stem Cell and Regenerative Fellowship Program, visit the ISSCA website or contact Global Stem Cells Group.
About Marmara University
Marmara University is a leading research university nestled in Istanbul, Turkey. It’s a distinguished academic institution with high authority in scientific research and academic excellence, specifically in medicine. The university provides undergraduate, graduate, and doctorate degrees, as well as certificate programs. Marmara University also boasts state-of-the-art facilities and dedicated faculty that chronicle its dedication to giving scholars world-class learning experiences and contributing to the advancement of knowledge in wide-ranging fields.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA is Pleased to Announce the Launch of its Comprehensive Online Course in Regenerative and Functional Medicine for Obesity Management
The International Society for Stem Cell Application (ISSCA) is proud to announce the launch of its latest online course, “Curso en Medicina Funcional Regenerativa y Obesidad / Course in Functional Regenerative Medicine and Obesity.” This comprehensive course is designed to provide students with a deep understanding of various aspects of obesity treatment, metabolic syndrome, and post-procedure management of patients.
“This course should provide students with the knowledge and skills necessary to succeed in the field of regenerative and functional medicine,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “We are committed to providing students with a comprehensive understanding of the latest advancements in the field and how to effectively care for patients”.
The course covers various key concepts of regenerative and functional medicine for obesity management, and gastric balloon, a safe and effective non-surgical treatment, as one of them. The course will feature in-depth insights into the fundamentals of this procedure and how they can be used to help patients achieve and enjoy healthy weight loss. Additionally, post-procedure management approaches and protocols, will be covered.
Apart from balloon therapy, the course will also explore a wide range of other related topics, such as vitamins, exosomes, trace elements, minerals, hydrolyzed collagen, and more, and their significance in obesity management. These topics should prove useful to practitioners and course other course attendees in understanding metabolic syndrome and the best post-procedure practices for managing patients.
The course will be taught by two highly experienced and well respected professionals in the field of medicine:
Dr. Mario Ojeda, Director and Member of the Chilean Society of Aesthetic Medicine and Surgery (SOCHIMCE). An international reference and renowned expert in various areas, including obesity, intragastric balloons, endoscopic gastroplasty, stem cells, gastroenterology, digestive endoscopy, and colonoscopy, Dr. Mario Ojeda is “pleased to be part of this comprehensive online course and to provide students with the necessary knowledge and skills to advance the field of regenerative and functional medicine.”
Dr. Silvina Pastrana, Head of the ISSCA chapter in Latin America. She is a specialist in general surgery and has extensive experience in aesthetic and anti-aging medicine, orthomolecular medicine and nutrition, cellular therapies, and more. As a trainer in cellular therapies, she is well-equipped to provide students with a comprehensive understanding of the latest advancements in the field.
ISSCA is committed to advancing knowledge in regenerative and functional medicine for better obesity management. This comprehensive online course should provide physicians and specialists with a complete understanding of the latest advancements in the field and how to effectively manage patients, post-procedure.
For more information about the course and how to enroll, please visit the ISSCA visit the ISSCA website, send an email to info@stemcellsgroup.com, or call +1305 560 5337
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advancements in regenerative medicine. It is the educational division of the Global Stem Cells Group focused on promoting excellence and standards in the field of regenerative and functional medicine.
Through training and advancement courses, ISSCA aims to encourage physicians and specialists to practice new and advanced regenerative medicine approaches to benefit patients globally. It also ensures that practitioners learn, meet, and adhere to the necessary regenerative medicine standards and certifications.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group (GSCG) and International Society for Stem Cell Application (ISSCA) to Participate in Dubai Stem Cell Congress 2023
MIAMI, Florida, February 15, 2023 – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), are proud to announce their participation as sponsors and co-organizers of the Dubai Stem Cell Congress 2023. The congress, endorsed by the Hortman Stem Cell Laboratory, will take place on the 27th and 28th of February 2023 at the prestigious Waldorf Astoria on The Palm in Dubai.
The congress will bring together international experts in regenerative medicine and stem cell research from around the world to share their knowledge, experiences, and insights with the academic community and the general public. The event will also provide a platform for patients to share their success stories of stem cell therapy and how it has helped them overcome various life-threatening diseases.
“We are honored to welcome you to the first edition of the Dubai Stem Cell Congress 2023, which will host international experts in the field of Regenerative Medicine & Stem Cell Research from around the world,” said Dr. Fatma Alhashimi, Chairman of Dubai Stem Cell Congress. “We will be showcasing cutting-edge data, stem cell technologies, and advanced applications.”
GSCG will showcase its range of cellular products and equipment, including exosomes for topical and intravenous use, Mesenchymal Stem Cells (MSC), Bone Marrow Kit, PRP Kit, Fat Kit for obtaining Stromal Vascular Fraction (SVF), workstation, and laboratory equipment. ISSCA, on the other hand, will be represented with its training, congresses, conferences, and the fellowship in Cellular Therapies.
“Our mission is to make cellular therapies a reality for both doctors and patients, and we are happy to continue that mission by sharing our knowledge and showcasing our Cellgenic branded Cellular products and equipment at the congress,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for ISSCA.
With over 25 world-class international speakers, including ISSCA-certified speakers, the congress will feature a variety of panel discussions, lectures, and presentations on the latest innovative technologies in stem cell and regenerative medicine.
ISSCA-certified speakers and experts who will be presenting lectures at the congress include the following:
- Erdinç Civelek, a brain surgeon at Gaziosmanpaşa Taksim Hospital for Research and Education in Turkey.
- Dr. Serdar Kabataş, a brain surgeon at Gaziosmanpaşa Taksim Research and Education Hospital in Turkey.
- Abdulmajeed Hamadi, a consultant hematologist and pioneer in transplantation and stem cell therapy with an FRCP designation in Iraq.
- Salih Yildirim, the Director of Overseas Operations of ISSCA and a member of the Board of Directors of the Global Stem Cell Group and Director of International Operations.
- Benito Novas, the Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for the Application of Stem Cells in the USA.
Among the esteemed speakers at the event are:
Prof. Anil Dhawan, Dr. Frances Verter, Dr. Masayo Takahashi, Dr. Essam Abdelalim, Prof. Shuibing Chen, Prof. John E. Wagner, Mrs. Kim Petrella, Dr. Edward Guindi, Dr. Mazaiah Yaacob, Dr. Mohammed Moulay, Mr. Oliver Papavlassopoulos, Dr. Sean Ng, Dr. Chiara Cugno, Dr. Siti Aminah, Mr. Thomas Moss, Prof. Dr. Tim Schulz, Dr. Luis Saraiva, Mrs. Renata Mihályová, Dr. Srinivasan Periathiruvadi and Dr. Ahmed Foul.
For the first time in the UAE, patients will have the opportunity to share their success stories of stem cell therapy, including the story of Mahra, a UAE national and survivor of Thalassemia, and the world’s first cord blood patient, Matthew Farrow.
Stem cell therapy is the present and future of medicine and holds the “Hope That Brings Life” to many patients in need. The Dubai Stem Cell Congress 2023 is a landmark event that will bring together leading experts, patients, and members of the academic community to share their experiences and knowledge about stem cell therapy and its advancements.
To learn more about the Dubai Stem Cell Congress 2023 and to make a reservation, visit the https://dubaistemcellcongress.com/ website, email info@stemcellsgroup.com, or call +1 305 560 5337.
About Hortman Stem Cell Laboratory
Mr. Darius Curta Managing Director of Hortman Healthcare Investment – Hortman Stem Cell Laboratory is the first state-of-the-art laboratory within the field of Stem Cells and Regenerative Medicine, focused on providing top-notch cord blood banking solutions. Additionally, our institution will be facilitating the first ever clinical trials in stem cell research in UAE. Hortman Stem Cell Laboratory, located at Golden Mile, Palm Jumeirah, consists of GMP Laboratories & ISO Clean Rooms for stem cell isolation, culture & expansion. Such a facility enables us to provide a solid foundation for successfully establishing an awareness and understanding of stem cells within the Middle Eastern Region. Hortman is leading that charge at the forefront of the research community.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA’s On-site Training in Portugal
MIAMI, Florida, January 23, 2023 – The Global Stem Cells Group (GSCG) announces its long-awaited hands-on training this March 9th, 10th & 11th, 2023
The GSCG, through its International Society for Stem Cell Application (ISSCA) division, is holding a personalized, hands-on training course at Regenera clinic, located in Oeiras, Lisboa, Portugal. Industry-leading instructors across the regenerative medicine field will lead this onsite training course. We believe this course is a Total Solution for clinics as ISSCA teams will teach and train doctors and caregivers on the recent advances in regenerative medicine and cellular-based treatments.
Lisboa’s First On-site Training
Benito Novas, CEO of Global Stem Cells Group and Vice President of ISSCA, notes that “regenerative medicine is the future of health and beauty industries as more research is conducted and products developed for doctors to offer a superior service.”
Benito adds, “the training course will take a highly visual format with global experts interacting with trainees and live patients used to teach about different stem cell reintegration and procedural techniques with locally available tools and facilities.
The Lisboa training is the first in the country to bring clinics into the fold of regenerative medicine and stem cell treatments. Regenera clinic will be the first to be ISSCA certified and apply cellular therapies and regenerative medicine. Dr. Roni Lara Moya will be appointed Portugal Chapter director on 9th March.
The course design considers the needs of local trainees using a thorough scheduling process. Initial consultations between the trainees and ISSCA will inform equipment and kits availability, materials, underlying costs, and any other needs to be met during the main event.
What is the On-site Training About?
The following are some of the areas the onsite-training course will focus on:
1. Learning from Experts
A panel of stem cell therapy and regenerative medicine experts will lead the one-on-one training sessions. Cell therapy, skin regeneration techniques, bone marrow extraction, tissue engineering, and many more applications of advanced technologies to advance personalized health will be practically illustrated.
2. Trainees-Centered Treatment Protocols
The training course is personalized to every doctor and clinician’s specialization and the illness they are targeting. For example, stem cell treatment sessions will include various reintegration methods based on patients’ medical history and condition. The trainees will also have a first-hand view of how technology pushes the boundaries of regenerative medicine from research to the derivation of cell lines and, as we are all working to the possible future of genetic alteration.
Local nurses and medical assistants will also have a chance to be part of the process by going through a fully skilled procedural session that improves their assistance to the doctors.
3. International Certification
As an acclaimed stakeholder in regenerative medicine and stem cell treatment, ISSCA offers globally recognized certification to doctors and practitioners, highlighting their fascinating journey in this highly demanded field. According to the appointed chapter director of Portugal, Dr. Roni Lara Moya- “the upcoming onsite training is one of its kind ever conducted in the country. Dr. Moya asserts that “the collaboration between ISSCA and Regenerative Biomedicine Regenerative Clinic stems from a growing demand for new technologies and cutting-edge treatments that support patients’ positive health outcomes.”
4. Trends in Regenerative & Stem Cell Treatment
The training will cover stem cell and regenerative medicine’s practical, legal, technical, and ethical aspects. Laws, technological developments, and ethical concerns will be a critical part of the training course.
All are welcome to share the fantastic excitement of stem cell science and its promising future.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Mesenchymal Stem Cells For Cardiovascular Diseases
Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
Refractory angina
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
ISSCA to Conduct Regenerative Medicine Conference in Cancún, México
Miami, FL, December 19, 2022 – The International Association for Stem Cell Application (ISSCA) has announced plans to host Applications of Stem Cell Therapies in Medicine and Aesthetic Surgery, a regenerative medicine conference, in Cancun, Mexico, April 22, 23, and 24, 2023.
Growing knowledge can turn the tide in the clinical and translational spectrum of stem-cell-based research and therapy, and several obstacles must be overcome. ISSCA’s International Conference, champions new ideas to propel the shift from traditional healthcare to regenerative medicine and therapies. The Conference will also emphasize the role of cutting technology and developments in all areas of stem cell research.
April 22nd & 23rd
The Cancun event will feature a panel of internationally renowned experts on stem cells and regenerative medicine, who will offer a two-day rigorous scientific discourse on critical topics in stem cell research and clinical applications. Topics of focus at the conference include: Tissue engineering and regenerative medicine; updates in Stem Cell research Clinical applications of regenerative medicine and cellular therapies; the latest methods of harvest and isolation, and Non-invasive surgical protocols; strategies for successful delivery of cell products; Ethical and regulatory issues in stem cell technology; and taking advantage of the latest technologies to improve marketing and networking.
April 24th
The third day of the conference (April 24th) will involve intensive hands-on training sessions with ISSCA-certified instructors on stem cell therapy’s aesthetic and clinical applications.
Participants will gain experience and access to different technologies, brands, and products for stem cell therapy.
The leading international conference offers an excellent opportunity for medical practitioners and stakeholders to network and learn from the best in the industry.
All practitioners and stakeholders in the medical sector are invited, including:
- Doctors Researchers & innovators,
- Decision-makers and funding agencies,
- Experts seeking collaborative work on stem cell technology,
- Professional bodies, and
- Marketing professionals.
To learn more about the ISSCA Cancun, Mexico conference and to make a reservation, visit the https://www.issca.us/issca-world-conferences/ website, email info@stemcellsgroup.com, or call +1305 560 5337.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Release
Regenerative Medicine – An Overview On Stem Cell Therapy
Stem cell therapy is a form of regenerative medicine designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions.
What is stem cell therapy?
The term stem cell therapy refers to any treatment involving the use of viable human stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells. By being able to differentiate into the specific cell types necessary for repairing diseased tissues, stem cells are the ideal solution for tissue and organ transplantation.
As stem cell-based therapies are complex, researchers often seek stable, safe, and readily available sources of stem cells that can differentiate into multiple lineages. As such, choosing stem cells with clinical applications in mind is of the utmost importance
The hierarchy of stem cells
In general, stem cells fall into three categories. In addition to self-renewal, all three share a unique ability to differentiate. However, stem cells do not exist in a homogeneous form, but rather in a developmental hierarchy. Among all stem cells, totipotent cells are the most basic and least developed. These cells are capable of developing into a complete embryo while forming the extraembryonic tissue at the same time. During the fertilization of the ovum, this unique property begins and ends when the embryo reaches the stage of four to eight cells.
As the cell divides further, it loses its totipotency property and becomes a pluripotent cell, capable of dividing into each of the three embryonic germ layers (ectoderm, mesoderm, and endoderm). These cells are referred to as “embryonic stem cells” and are isolated from the inner cell mass of the blastocyst after the embryo is destroyed.
The property of pluripotency is lost with successive divisions, resulting in a more limited differentiation capability in which the cells can only differentiate into limited types of cells related to their origins. “Adult stem cells” have this property, which helps maintain homeostasis throughout the organism’s lifespan. It is known that adult stem cells are present in most specialized tissue types of the body in a metabolically quiescent state, including bone marrow and oral and dental tissue.
According to many authors, adult stem cells are the gold standard for stem cell-based therapies. A number of trials involving adult stem cells have shown promising results, especially in the transplantation of hematopoietic stem cells.
Stem cell research for treating disease
In 2006, Shinya Yamanka achieved a scientific breakthrough in stem cell research by generating cells with the same properties as embryonic stem cells. In fully differentiated somatic cells, namely fibroblasts, four transcription factors were transiently over-expressed, including OCT4, SOX2, KLF4, and MYC. As a result of the discovery of these cells, stem cell research has been transformed ever since. Similar to embryonic stem cells, these cells are capable of dividing into any of the germ layers. As a result of the development of iPSC technology, disease identification and treatment have become more innovative. IPSCs are therefore promising as a source of pluripotent derived patient-matched cells that can be used for autologous transplants because they can be generated from the patient’s own cells.
It is believed that stem cells, due to their unique capacity to regenerate, may hold new potential for treating diseases such as diabetes and heart disease. Despite this, there remains much work to be done in the laboratory and clinic to determine how these cells can be used in regenerative or reparative medicine to treat diseases.
Studies of stem cells in the laboratory allow scientists to gain a better understanding of the cells’ essential properties as well as what makes them different from specialized cell types. Researchers are already using stem cells to test new drugs and develop model systems for studying normal development and identifying the causes of birth defects in the laboratory.
The study of stem cells continues to advance our understanding of the development of an organism from a single cell and of how healthy cells replace damaged cells in adult organisms. Research on stem cells is one of the most fascinating areas of contemporary biology, but, as with many fields of science that expand rapidly, it raises as many questions as it answers.
To learn more about stem cells, cellular therapies and new medical protocols using exosomes sign up for our international certification in regenerative medicine at www.issca.us
- Published in Blog